Skip to main content
. 2013 Aug 20;7:189–198. doi: 10.2147/BTT.S34942

Figure 1.

Figure 1

Kaplan–Meier analysis of overall survival in (A) COMFORT-I21 and (B) COMFORT-II20 with 24 months of follow-up.

Note: aP-values and CIs are unadjusted for repeat analyses.

Republished with permission of American Society of Hematology; High Wire Press, from A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Mascarenhas J, Hoffman R. Blood. 121(24):2013; permission conveyed through Copyright Clearance Center, Inc.59

Abbreviations: CI, confidence interval; HR, hazard ratio; BAT, best available therapy; COMFORT, COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment.